Andrew Johns

7PUBLICATIONS
48CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Nov 05, 2026
Postoperative Neuromuscular Paresis and Overlap Syndrome Related to Immune Checkpoint Inhibitors: A Case Report.

|Jun 23, 2026
Front-line chemo-immunotherapy for advanced penile cancer: ready for prime time?

|Mar 09, 2026
Impact of proton pump inhibitors on immunotherapy is modulated by prior chemotherapy and linked to gut microbiome-immune cell signatures.

Annastasia Petouhoff, Ryan Hicks, Marium Husain

|Aug 25, 2025
High-Dose Chemotherapy for Multiply or Poor-Risk Relapsed Germ Cell Tumors.

Yago Nieto, John F Ward, Wayne Hofstetter

|Mar 13, 2024
Efficacy, Safety, and Tolerability of Tivozanib in Heavily Pretreated Patients With Advanced Clear Cell Renal Cell Carcinoma.

Andrew C Johns, Matthew T Campbell, Mamie Gao

|Feb 04, 2023
Association of medical comorbidities and cardiovascular disease with toxicity and survival among patients receiving checkpoint inhibitor immunotherapy.

Andrew C Johns, Mike Yang, Lai Wei

Pageof 2

Frequent Collaborators

3 joint publications

Daniel Spakowicz

2 joint publications

Lai Wei

2 joint publications

Dwight H Owen

1 joint publications

Mingjia Li